Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it
Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin – on day one after the innovative drug from Boehringer Ingelheim (BI) went
Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin – on day one after the innovative drug from Boehringer Ingelheim (BI) went